Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.

Stanley B, Hollis RL, Nunes H, Towler JD, Yan X, Rye T, Dawson C, Mackean MJ, Nussey F, Churchman M, Herrington CS, Gourley C.

Gynecol Oncol. 2019 Feb;152(2):278-285. doi: 10.1016/j.ygyno.2018.11.030. Epub 2018 Nov 28.

PMID:
30501904
2.

A cautionary lesson on the use of targeted methods for EGFR mutation analysis: a case report.

Walsh K, Wallace WA, Butler R, Mackean MJ, Harrison DJ, Stirling D, Oniscu A.

J Clin Pathol. 2014 Aug;67(8):734-5. doi: 10.1136/jclinpath-2014-202313. Epub 2014 May 7.

PMID:
24811487
3.

Histologic assessment of tumor-associated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer.

Wang W, Hodkinson P, McLaren F, Mackean MJ, Williams L, Howie SEM, Wallace WAH, Sethi T.

Chest. 2013 Jan;143(1):146-151. doi: 10.1378/chest.12-0681.

PMID:
22847040
4.

Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.

Faluyi OO, Gourley C, Smyth JF, Faratian D, Williams AR, Rye T, Rye R, Stewart M, Mackean MJ.

Int J Gynecol Cancer. 2010 Dec;20(9):1511-7.

PMID:
21370594
5.

Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.

Ironside JA, English JF, Kerr GR, Price A, Little FA, Erridge SC, Mackean MJ.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):550-3. doi: 10.1016/j.clon.2010.05.013. Epub 2010 Jun 2.

PMID:
20627674
6.

Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.

Storey DJ, Colvin LA, Mackean MJ, Mitchell R, Fleetwood-Walker SM, Fallon MT.

J Pain Symptom Manage. 2010 Jun;39(6):e2-4. doi: 10.1016/j.jpainsymman.2010.02.004. No abstract available.

PMID:
20538177
7.

How many cisplatin administration protocols does your department use?

Greystoke AP, Jodrell DI, Cheung M, Rivans I, Mackean MJ.

Eur J Cancer Care (Engl). 2010 Jan 1;19(1):80-90. doi: 10.1111/j.1365-2354.2007.00908.x. Epub 2009 Aug 25. Review.

PMID:
19708939
8.

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.

Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP.

Clin Cancer Res. 2007 Jun 15;13(12):3617-22.

9.

Improving outcomes for limited stage small cell lung cancer patients in Scotland with concomitant chemoradiation.

Law AB, Erridge SC, MacKean MJ, Kerr GR, Ironside JA, Little FA, Price A.

Clin Oncol (R Coll Radiol). 2007 Apr;19(3):188-93. Epub 2007 Feb 20.

PMID:
17359905
10.

Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival.

Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, Brown R.

J Clin Oncol. 2000 Jan;18(1):87-93. Erratum in: J Clin Oncol 2000 Feb;18(4):944.

PMID:
10623697
11.

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.

Strathdee G, MacKean MJ, Illand M, Brown R.

Oncogene. 1999 Apr 8;18(14):2335-41.

12.

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

Mackean MJ, Kerr D, Lesko M, Svedberg A, Hansson F, Jodrell D, Cassidy J.

Br J Cancer. 1998 Dec;78(12):1620-3.

13.

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

Mackean MJ, Cassidy J, Jodrell DI, Paul J, Reed NS, Canney PA, Yosef H, Habeshaw T, Robertson AG, McInnes A, Twelves CJ.

Br J Cancer. 1998 May;77(9):1480-6.

Supplemental Content

Loading ...
Support Center